You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
A phytoestrogen with antitumor, antioxidant, antiplatelet, anti-inflammatory and antifungal effects. Inhibits cytochrome P450 1A1 (IC50 = 23 μM) and displays mixed agonist/antagonist actions at ERα and ERβ estrogen receptors. Converted into the anticancer agent piceatannol (Cat. No. 1554) by cytochrome P450 1B1. Activates autophagy. Also activates TRPA1 in prostate cancer-associated fibroblasts. Also SIRT1 activator.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solubility||Soluble to 100 mM in ethanol and to 100 mM in DMSO|
References are publications that support the biological activity of the product.
Baur and Sinclair (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat.Rev.Drug Discov. 5 493 PMID: 16732220
Bowers et al (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β. Endocrinology 141 3657 PMID: 11014220
Chun et al (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem.Biophys.Res.Commun. 262 20 PMID: 10448061
Fremont (2000) Biological effects of resveratrol. Life Sci. 66 663 PMID: 10680575
Kimura et al (1985) Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim.Biophys.Acta 834 275 PMID: 3922423
Baptista et al (2013) Regulation of histone H2A.Z exprsesion is mediated by sirtuin 1 in prostate cancer. Oncotarget 4 1673 PMID: 24127549
Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. PMID: 28529316
Vancauwenberghe et al (2017) Activation of mutated TRPA1 ion channel by resveratrol in human prostate cancer associated fibroblasts (CAF). Mol.Carcinog. 56 1851 PMID: 28277613
If you know of a relevant reference for Resveratrol, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Resveratrol, Resveratrol supplier, Antitumor, anti-oxidant, agent, Cyclooxygenase, inhibitors, inhibits, COX, Oxygenases, Oxidases, Antiangiogenics, Antioxidants, Class, III, HDACs, (Sirtuins), Autophagy, TRPA1, 1418, Tocris Bioscience
7 Citations for Resveratrol
Citations are publications that use Tocris products. Selected citations for Resveratrol include:
Wang et al (2013) Active Constituents from Liriope platyphylla Root against Cancer Growth In Vitro. Cancer Res 2013 857929 PMID: 23762164
Chen et al (2014) A critical role for IF. regulatory factor 9 in cerebral ischemic stroke. J Neurosci 34 11897 PMID: 25186738
Rojas et al (2014) Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Front Cell Neurosci 8 24 PMID: 24570655
Jiang and Zsombok (2014) Regulation of neurons in the dorsal motor nucleus of the vagus by SIRT1. Front Neurosci 7 270 PMID: 24454277
Ohshiro et al (2007) Identifying the estrogen receptor coactivator PELP1 in autophagosomes. Br J Pharmacol 67 8164 PMID: 17804729
Meftahi et al (2015) Suppressive Effects of Resveratrol Treatment on The Intrinsic Evoked Excitability of CA1 Pyramidal Neurons. Evid Based Complement Alternat Med 17 532 PMID: 26464825
Pacholec et al (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285 8340 PMID: 20061378
Do you know of a great paper that uses Resveratrol from Tocris? Please let us know.
Reviews for Resveratrol
There are currently no reviews for this product. Be the first to review Resveratrol and earn rewards!
Have you used Resveratrol?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.